June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
84 citations
,
September 2008 in “Developmental biology” Retinoic acid-binding proteins in skin are regulated by β-catenin and Notch signalling.
1 citations
,
November 2025 in “Journal of Dermatological Treatment” This prospective cohort study evaluated the real-world effectiveness and safety of Baricitinib in 48 adults with severe alopecia areata over a 12-month period. The study found that Baricitinib is effective and safe for managing severe AA, with the primary endpoint being a SALT score of less than 20% sustained over two consecutive assessments. Favorable responses were associated with lower baseline SALT scores, shorter disease duration, and higher basal erythrocyte sedimentation rates. No serious adverse events were reported, emphasizing the importance of early intervention and appropriate patient selection for optimal outcomes.
September 2023 in “Drugs in context” Baricitinib is a promising treatment for alopecia areata.
January 2024 in “Case Reports in Dermatological Medicine” Baricitinib may effectively treat nail changes in alopecia areata.
2 citations
,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
Introducing the OTC gene improved symptoms in mice with OTC deficiency.
January 2024 in “Genetics in Medicine Open” Adults with Tatton-Brown-Rahman syndrome may have serious heart problems and need lifelong heart monitoring.
August 2024 in “Journal of the American Academy of Dermatology” Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.
May 2025 in “International Journal of Molecular Sciences” Exosomes from rat hair follicle stem cells may help heal wounds and regenerate skin.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
January 2025 in “Ciência Rural” Improper use of benzyl benzoate on a dog can cause severe skin reactions.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
1 citations
,
January 2016 in “Journal of Biosciences and Medicines” The ACTH/MC2R system is crucial for controlling hair growth cycles in mice.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
September 2025 in “JID Innovations” Squaric acid dibutylester promotes hair growth by activating immune cells, especially macrophages.
January 2024 in “Acta dermato-venereologica”
6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
38 citations
,
September 2017 in “Journal of zoo and wildlife medicine” Oclacitinib maleate successfully treated alopecia in Andean bears.
1 citations
,
November 2002 in “Journal of dermatology” The antibody created from BCC tissues reacts similarly to both BCC and hair follicles, suggesting BCC may come from hair follicle cells.
1 citations
,
October 2024 in “JAAD Case Reports” Baricitinib effectively treated hair loss and inflammation in a patient with alopecia areata and lichen planopilaris.
July 2005 in “Journal of the American Academy of Dermatology”